Inside This Issue  by unknown
APRIL 1, 2014
VOLUME 63, NO. 12
JOURNAL of the AMERICAN COLLEGE of CARDIOLOGYInside This Issue
STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERGlobal Hospitalization for Heart Failure Registries 1123
Andrew P. Ambrosy, Gregg C. Fonarow, Javed Butler, Ovidiu Chioncel, Stephen J. Greene,
Muthiah Vaduganathan, Savina Nodari, Carolyn S. P. Lam, Naoki Sato, Ami N. Shah,
Mihai Gheorghiade
Heart failure is a global pandemic and results in more than 1 million hospitalizations annually
in both the United States and Europe. Heart failure patients continue to experience
unacceptable high post-discharge mortality, and readmission rates that have not changed in
the last decade. This paper reviews global hospitalized heart failure (HHF) registries to
describe patient characteristics, management, outcomes and their predictors, quality
improvement initiatives, regional differences, and limitations of available data. Based on the
lessons learned, the authors propose a road map for the design and conduct of future HHF
registries.VIEWPOINT AND
COMMENTARYVIEWPOINT AND COMMENTARYIschemia, Plaque Burden, and Disease Progression 1134
Rishi Puri, Stephen J. Nicholls, Stephen G. Ellis, E. Murat Tuzcu, Samir R. Kapadia
Prior necropsy studies have delineated the morphological characteristics of high-risk or
‘vulnerable’ coronary plaque segments. The authors present more contemporary, in vivo
evidence that suggests that the overall burden of atherosclerosis, its rate of progression, and
subsequent ischemic potential determine the risk of incident clinical events. Implications of
these ﬁndings on future trial designs are also discussed.
Commentary: Pedro R. Moreno, Jagat Narula p. 1141(continued on page A-27)
APRIL 1, 2014 (continued) A-27CLINICAL RESEARCH CLINICAL TRIALSFFR Derived From Standard Acquired Coronary CTA 1145
Bjarne L. Nørgaard, Jonathon Leipsic, Sara Gaur, Sujith Seneviratne, Brian S. Ko,
Hiroshi Ito, Jesper M. Jensen, Laura Mauri, Bernard De Bruyne, Hiram Bezerra,
Kazuhiro Osawa, Mohamed Marwan, Christoph Naber, Andrejs Erglis, Seung-Jung Park,
Evald H. Christiansen, Anne Kaltoft, Jens F. Lassen, Hans Erik Bøtker, Stephan Achenbach,
on behalf of the NXT Trial Study Group
The NXT (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps) trial
determines the ability of noninvasive fractional ﬂow reserve (FFR) derived from coronary
computed tomography (CTA) datasets (FFRCT) for the diagnosis of myocardial ischemia in
patients with suspected stable coronary artery disease (CAD). A total of 254 patients
undergoing clinically indicated invasive coronary angiography (ICA) for suspected CAD
additionally underwent prior CTA. FFRCTwas calculated and compared with FFRmeasured
invasively. Per-patient sensitivity and speciﬁcity to identify myocardial ischemia were 86% and
79% for FFRCT versus 94% and 34% for coronary CTA and 65% and 83% for ICA,
respectively. The study concluded that FFRCT provides high diagnostic accuracy and
discrimination for the diagnosis of hemodynamically signiﬁcantCAD,with invasive FFR as the
reference standard. When compared with anatomic testing coronary CTA, FFRCT leads to a
marked increase in speciﬁcity.
Editorial Comment: Harvey S. Hecht, p. 1156CLINICAL TRIALSTranscatheter Versus Surgical Perimembranous VSD Closure 1159
Jian Yang, Lifang Yang, Shiqiang Yu, Jincheng Liu, Jian Zuo, Wensheng Chen, Weixun Duan,
Qijun Zheng, Xuezeng Xu, Jun Li, Jun Zhang, Jian Xu, Lijun Sun, Xiuling Yang, Lize Xiong,
Dinghua Yi, Lei Wang, Qingchun Liu, Shuping Ge, Jun Ren
This trial evaluates the safety and efﬁcacy of the surgical versus transcatheter approach to
correct perimembranous ventricular septal defect (pmVSD). A total of 229 children with
pmVSD were randomly assigned to surgical or transcatheter intervention. The 2-year follow-
up data revealed that neither group had mortality or major complications. There were no
differences between the 2 groups in closure rate, adverse events, and complications. The
authors conclude that transcatheter device closure and surgical repair are effective interventions
with excellent midterm results for treating pmVSD in children. Transcatheter device closure
has fewer incidences of myocardial injury, less blood transfused, faster recovery, shorter
hospital stay, and lower medical expense.(continued on page A-28)
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Tajinder P. Singh, Carly E. Milliren, Christopher S. Almond, Dionne Graham
The study objective was to assess survival beneﬁt from heart transplant (HT) upon receiving
HT close to listing in candidates stratiﬁed by the risk of wait-list mortality. Beneﬁt deﬁned as
a reduction in the risk of 90-day and 1-year mortality on receiving HT close to listing, in
candidates stratiﬁed by the risk of wait-list mortality. Patients who were listed for HT (2007
to 2010) were analyzed and a model to predict the risk of wait-list mortality within 90 days
was developed. Of 10,159 patients, 596 (5.9%) died within 90 days and 1,054 (10.4%) within
1 year without receiving transplant. Of 5,720 HT recipients with 1-year follow up, 576
(10.1%) died within 1 year. The risk of death within 90 days on the wait list increased from
1.6% to 19% across the 10 risk groups. While survival beneﬁt from HT generally increases
with increasing risk of wait-list mortality, there is no measurable beneﬁt in many candidates
at the lower end of the risk spectrum.
Editorial Comment: Donna M. Mancini, P. Christian Schulze, p. 1179HEART FAILUREResting Heart Rate Predicts LV Dysfunction and Heart Failure 1182
Anders Opdahl, Bharath Ambale Venkatesh, Veronica R. S. Fernandes, Colin O. Wu,
Khurram Nasir, Eui-Young Choi, Andre L. C. Almeida, Boaz Rosen, Benilton Carvalho,
Thor Edvardsen, David A. Bluemke, João A. C. Lima
The investigators evaluate the relationship between baseline resting heart rate and incidence
of heart failure (HF) and regional left ventricular (LV) dysfunction in participants in MESA
(Multi-Ethnic Study of Atherosclerosis). Incident HF was registered (n ¼ 176) during
follow-up (median 7 years) in those who underwent cardiac magnetic resonance imaging
(n ¼ 5,000). Changes in ejection fraction (EF) and peak circumferential strain (ECC) were
measured as markers of developing global and regional LV function in 1,056 participants
imaged at baseline and 5 years later. Results revealed that elevated resting heart rate is
associated with increased risk of incident HF in asymptomatic participants in MESA. Higher
heart rate was related to development of regional and global LV dysfunction independent of
subclinical atherosclerosis and coronary heart disease.(continued on page A-29)
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Anne-Christine Ruwald, Grzegorz Pietrasik, Ilan Goldenberg, Valentina Kutyifa,
James P. Daubert, Martin H. Ruwald, Christian Jons, Scott McNitt, Paul Wang,
Wojciech Zareba, Arthur J. Moss
This study aimed to investigate the effect of both history of intermittent atrial
tachyarrhythmias (IATs) and in-trial IAT on the risk of heart failure (HF) or death
comparing cardiac resynchronization therapy with deﬁbrillator (CRT-D) with implantable
cardioverter-deﬁbrillator (ICD) treatment in mildly symptomatic HF patients with left
bundle branch block (LBBB). A total of 1,264 patients with LBBB enrolled in the
MADIT-CRT (Multicenter Automatic Deﬁbrillator Implantation Trial With Cardiac
Resynchronization Therapy) were analyzed. Results revealed that the overall beneﬁcial effect
of CRT-D versus ICD on the risk of HF or death was not signiﬁcantly different between
LBBB patients with or without history of IAT. The study shows that in MADIT-CRT, the
clinical beneﬁt of cardiac resynchronization therapy in LBBB patients was not attenuated by
prior history of IATs or by the development of in-trial atrial tachyarrhythmias.
Editorial Comment: Tiziana Chiriaco, Fabrizio Ammirati, p. 1198(continued on page A-30)
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Steven A. Lubitz, Kathryn L. Lunetta, Honghuang Lin, Dan E. Arking, Stella Trompet, Guo Li,
Bouwe P. Krijthe, Daniel I. Chasman, John Barnard, Marcus E. Kleber, Marcus Dörr, Kouichi Ozaki,
Albert V. Smith, Martina Müller-Nurasyid, Stefan Walter, Sunil K. Agarwal, Joshua C. Bis,
Jennifer A. Brody, Lin Y. Chen, Brendan M. Everett, Ian Ford, Oscar H. Franco, Tamara B. Harris,
Albert Hofman, Stefan Kääb, Saagar Mahida, Sekar Kathiresan, Michiaki Kubo, Lenore J. Launer,
Peter W. Macfarlane, Jared W. Magnani, Barbara McKnight, David D. McManus, Annette Peters,
Bruce M. Psaty, Lynda M. Rose, Jerome I. Rotter, Guenther Silbernagel, Jonathan D. Smith,
Nona Sotoodehnia, David J. Stott, Kent D. Taylor, Andreas Tomaschitz, Tatsuhiko Tsunoda,
Andre G. Uitterlinden, David R. Van Wagoner, Uwe Völker, Henry Völzke, Joanne M. Murabito,
Moritz F. Sinner, Vilmundur Gudnason, Stephan B. Felix, Winfried März, Mina Chung,
Christine M. Albert, Bruno H. Stricker, Toshihiro Tanaka, Susan R. Heckbert, J. Wouter Jukema,
Alvaro Alonso, Emelia J. Benjamin, Patrick T. Ellinor
Atrial ﬁbrillation (AF)-associated loci span broad genomic regions and may contain multiple
susceptibility signals. The authors attempt to identify nonredundant AF genetic susceptibility
signals and examine their cumulative relation to AF risk. Association testing conditioned on
the most signiﬁcant independently associated genetic markers at 9 established AF loci were
performed on 64,683 individuals of European ancestry. At least 4 distinct AF susceptibility
signals were observed on chromosome 4q25 upstream of PITx2, but not at the remaining
8 AF loci. A multilocus score comprised of 12 genetic markers demonstrated an estimated
5-fold gradient in AF risk in those with either European or Japanese ancestry. Similar
spectrums of risk associated with these markers were observed in individuals of Japanese
ancestry that were studied. The study shows that chromosome 4q25 AF locus is
architecturally complex and harbors at least 4 AF susceptibility signals in individuals of
European ancestry.
Editorial Comment: Dan M. Roden, p. 1211HYPERTENSIONVitamin D, Parathyroid Hormone, and Hypertension 1214
Adriana J. van Ballegooijen, Bryan Kestenbaum, Michael C. Sachs, Ian H. de Boer, David S. Siscovick,
Andrew N. Hoofnagle, Joachim H. Ix, Marjolein Visser, Ingeborg A. Brouwer
The authors investigate whether lower 25-hydroxyvitamin D and higher serum parathyroid
hormone concentrations are associated with incident hypertension. A total of 3,002 men and
women (age 45 to 84 years) enrolled in MESA (Multi-Ethnic Study of Atherosclerosis) and
free of cardiovascular disease and hypertension were studied. During a median follow-up of 9
years, 41% of the cohort developed hypertension. Compared with parathyroid hormone <33
pg/ml, parathyroid hormone 65 pg/ml was associated with a greater risk of hypertension
(hazard ratio: 1.28), after adjusting for potential confounders. The authors conclude that higher
serum parathyroid hormone, but not lower 25-hydroxyvitamin D, was associated with a greater
risk of incident hypertension.
